Articles tagged with Antibody Therapy
Researchers developed an integrated NMR and LC–MS approach to distinguish between stereochemical variants of methionine oxidation in antibody drugs. The method resolves subtle structural variations relevant to biologic drug quality, strengthening stability testing and quality assessment.
Researchers developed a novel NMR approach to analyze the structure of therapeutic antibodies without isotope labeling. The technique uses site-specific methyl signals to detect subtle structural variations, including glycosylation patterns and local flexibility. This method has significant implications for ensuring the quality of biol...
A newly described HIV antibody targets the V3 glycan site in a different manner than previously known antibodies, remaining effective against virus variants that are resistant to classical V3 antibodies. This breakthrough supports antibody therapy combinations that neutralize the virus more effectively.
SLAMF6 is a molecule on the surface of immune cells that prevents T cells from effectively attacking tumours. Researchers have developed new monoclonal antibodies that prevent SLAMF6 from interacting with itself, potentially offering an option for patients who no longer respond to PD1 or PDL1 treatments.
Researchers developed a PD-L1-binding antigen presenter that redirects antiviral antibodies to target cancer cells, transforming virus-specific immune memory into precision anti-cancer weapons. This strategy has significant potential for treating hard-to-treat cancers and represents a lower-cost, safer avenue for tumor immunotherapy.
Researchers at PolyU have identified a key driver of tumour growth in liver cancer and developed a monoclonal antibody that neutralises this protein. The antibody inhibits the growth and proliferation of FABP4-driven cancer stem cells, enhancing immune cell activity.
A study published in Microbiome found that gut microbiome-derived butyrate activates immune cells to enhance vaccine efficacy by promoting T follicular helper (Tfh) cell activity and mucosal antibody production. This discovery highlights the crucial role of gut environment regulation in controlling infections and enhancing vaccine resp...
Engineered yeast cells can mimic real cancer cells and be used to test new cancer immunotherapies much faster and cheaper than before. This new technology enables researchers to assess which CAR T variants are most promising much more quickly, leading to safer and more targeted cancer treatments.
The cGAS-STING pathway plays a crucial role in detecting cellular DNA, triggering type I interferons and cytokines, and modulating immune responses. Its therapeutic potential is being explored in cancer and various diseases, with promising preclinical evidence suggesting its potential as a target for next-generation immunotherapies.
The University of Texas MD Anderson Cancer Center has made significant advancements in cancer care through its collaborative efforts between clinicians and scientists. These breakthroughs include an immune-targeting vaccine that shows promise in intercepting cancer in patients with Lynch Syndrome, a novel immunotherapy that demonstrate...
Researchers have developed a new way to boost the immune system's response to cancer by using specially engineered antibodies. The antibodies work by clustering multiple immune cell receptors, amplifying the signal that tells T cells to attack cancer cells.
Researchers discovered that certain antibodies employ unusual tactics to block bacterial adhesion, including creating molecular wedges and conformational traps. These mechanisms could lead to the development of immune therapies targeting glycan-binding cell-attachment proteins produced by bacteria causing urinary tract infections.
Researchers developed an engineered antibody that outsmarts cytomegalovirus by avoiding its immune evasion strategies and activating immune cells to attack infected cells. This breakthrough could lead to safer and more effective treatments for vulnerable populations.
A new study developed an antibody that blocks several ways TNBC cells survive, grow, and evade the immune system. The antibody suppressed primary tumor growth and reenergized cancer-fighting immune cells, including T-cells and macrophages, in preclinical models.
A new study has developed a calcium-activated delivery system that enables more precise cancer treatment, reducing side effects and improving outcomes. The system uses a 'calcium switch' to target tumor cells, releasing a lethal payload deep within, while sparing healthy tissue.
Two first-in-class antibodies, C01 and C04, have been developed to inhibit inflammation in autoimmune diseases by blocking the high-affinity IgG receptor FcγRI. The antibodies were discovered using a unique immunization method and exhibit higher affinity for FcγRI than human IgG.
A new broad-spectrum antivenom developed by DTU researchers covers 17 African snake species and provides better protection against tissue damage, with a lower risk of immune reactions. The antivenom has shown impressive results in laboratory studies and could revolutionize the treatment of venomous snakebites in Africa.
Researchers developed a computational platform to design synthetic protein receptors that can detect tumor signals and boost T cell activity. The new receptors, called T-SenSERs, showed improved tumor control and longer survival in mouse models of lung cancer and multiple myeloma.
A new Alliance trial is exploring the effectiveness of a combination of targeted therapy and immunotherapy for patients with advanced adrenocortical carcinoma, a rare and aggressive cancer. The study aims to improve disease control and quality of life for patients with limited treatment options.
Scientists at King's College London have developed a potential antibody therapy strategy that restricts the growth of treatment-resistant breast cancers. The 'triple-engineered antibody' harnesses the body's immune defences to attack tumour cells and activates immune cells to kill cancer cells.
Researchers developed a novel technology to attach 'fake targets' to tumor cells, enabling immune cells to attack regardless of antigen presence. The Univody platform showed promising results in animal models, suppressing tumor growth and triggering broader immune activation.
New research explains why antibody-based drugs become too thick to be injected at high concentrations. Understanding the role of electrical charges, researchers can now predict behavior and develop more stable formulations.
Researchers at UMC Utrecht discovered that converting monoclonal antibodies from IgG to IgM isotype can significantly broaden their ability to recognize and bind multiple human-relevant bacterial pathogens. This finding could guide the future design of antibody therapies against bacterial infections.
A newly identified antibody, 04_A06, has been found to block 98.5% of over 300 different HIV strains in laboratory tests. In humanized mice models, the antibody reduced viral load to undetectable levels, offering a promising approach for HIV prevention and treatment.
Researchers at CU Anschutz discovered a genetic program within lymphatic endothelial cells that enables storage and archival of antigens, helping the immune system remember infections. This understanding could lead to improved vaccines and therapies by fine-tuning immune memory.
The partnership enables AI-driven design, antibody development, payload-linker synthesis, and clinical development to accelerate ADC drug discovery and development. The collaboration aims to deliver more effective treatment options for cancer patients worldwide by integrating cutting-edge technology and expertise.
Researchers developed a high-volume method to rapidly build and test large numbers of antibodies at once, accelerating antibody research and treatment development. The oPool+ display platform has potential applications in influenza vaccination research, infectious disease treatment, and cancer research.
A daily intranasal corticosteroid treatment with stapokibart resulted in reduced polyp size and improved nasal symptom severity after 24 weeks. Stapokibart, a novel monoclonal antibody, showed efficacy in treating severe uncontrolled chronic rhinosinusitis with nasal polyps.
A team of researchers has visualized the nanoscale architecture of CD20 receptors and their interactions with anti-CD20 antibodies using a novel super-resolution microscopy technique. The study reveals that structural changes in antibody design translate into different receptor patterns and cellular responses, opening up new pathways f...
A study found that immunoglobulin replacement therapy was ineffective in reducing serious infections requiring hospitalization among CLL patients. Despite increasing use of the therapy, infection rates remained high, highlighting a need for better clinical guidelines and evaluation of treatment duration.
A new study shows that delivering a single injection of gene therapy at birth may offer years-long protection against HIV. The treatment uses an adeno-associated virus to deliver instructions to muscle cells, which produce broadly neutralizing antibodies capable of neutralizing multiple strains of HIV.
Researchers found that certain antibodies can reduce antitumor immune cells, highlighting the need to consider ADCC activity when designing or selecting ICI therapeutics. This study could help improve cancer treatment by engineering antibodies that avoid damaging essential immune cells.
A novel nanocarrier system utilizing metal-polyphenols enables precise intracellular delivery of therapeutic antibodies into cancer cells. This technology overcomes endosomal entrapment, resulting in suppressed tumor growth and enhanced anti-cancer activity.
Researchers discovered LAG-3 inhibits T cell activity through spatial proximity to TCR, not ligand binding. This discovery enables precise modulation of autoreactive T cells in autoimmune diseases.
Researchers have developed a novel treatment approach for autoimmune diseases by engineering a protein that holds closely together two signaling complexes on T cells, shutting down those T cells in a limited way. This approach shows promise for treating conditions such as Type-1 diabetes and multiple sclerosis.
DB-1310, a HER3-targeted antibody-drug conjugate, has shown real potential as a new treatment option for patients with advanced solid tumors that have progressed after standard therapies. In an international clinical trial, DB-1310 demonstrated significant tumor shrinkage and delayed cancer growth in 44% of EGFR-mutant NSCLC patients.
The Experimental Drug Development Centre's EBC-129, an antibody-drug conjugate targeting pancreatic cancer, has received FDA fast track designation. The treatment is undergoing Phase 1 clinical trials and aims to provide new treatment options for patients with solid tumours.
Researchers at the University of Pennsylvania have created mirror-image molecules that both directly attack bacterial membranes and stimulate the immune system. The dual-action peptides have shown promise in treating infections by reducing bacterial counts and speeding healing, while also promoting sustained immune response.
Researchers developed a dual action immunotherapy using CAR-T cells targeting CD19 and CD22 proteins in B-ALL cancer cells, increasing the efficacy of treatment and reducing relapse rates.
Researchers have discovered a new druggable cancer target, NPM1, which is expressed on the surface of malignant AML cells. Monoclonal antibodies targeting NPM1 showed robust anti-tumor activity in multiple in vivo models of AML, with no apparent toxicity to non-cancerous blood cells and stem cells.
The study analyzed 54 U.S. studies and found no significant association with serious adverse events for oral antivirals like Paxlovid or monoclonal antibodies. Actemra was associated with infection and low white blood cell counts, while transfusions of convalescent plasma were linked to internal bleeding and blood clots.
Researchers have shed light on how a new type of antibody treatment works against ovarian cancer by reactivating patients' immune cells. The study shows that MOv18 IgE reverses the suppression of immune cells and induces them to kill cancer cells, providing new insights into this therapy.
A study using cryo-electron microscopy revealed that autoantibodies in myasthenia gravis disrupt acetylcholine receptor function by blocking or activating the immune system's complement pathway. This knowledge helps explain treatment variability and offers a foundation for personalized therapies targeting specific antibody interactions.
A new study suggests that blood cancer patients receiving Bruton Tyrosine Kinase inhibitors should continue their therapy while getting vaccinated against COVID-19. The IMPROVE trial found no improvement in antibody responses when BTKi therapy was paused for three weeks around the time of vaccination.
Researchers at KAIST have successfully developed a treatment method that restores vision by inducing retinal regeneration and vision recovery in disease-model mice. The approach involves blocking the PROX1 protein, which suppresses retinal regeneration, using an antibody developed by Celliaz Inc.
Scientists at Sanford Burnham Prebys developed a new method of generating antibodies by fusing two immune system proteins, enabling the creation of stable monoclonal antibodies. This breakthrough has potential applications in diagnosing and monitoring diseases such as lupus and cancers.
Researchers at Yale University discovered a lupus-related antibody that can trigger immune responses against certain tumors. The antibody has significantly prolonged survival in brain tumor models without radiation or chemotherapy. This breakthrough could lead to improved strategies for non-viral gene delivery and immunotherapy treatment.
Scientists from the University of Zurich created decoy molecules that bind to autoantibodies, preventing them from inhibiting type I interferons. This restoration restores antiviral effect on viruses like influenza, offering hope for treatment and reducing viral disease susceptibility.
The Chinese Medical Association has released updated guidelines for pediatric mycoplasma pneumoniae infection, emphasizing a multi-faceted diagnostic approach and evidence-based treatment strategies. The guidelines highlight the importance of accurate diagnosis and responsible antibiotic use to combat rising resistance.
A study has established the importance of immunoglobulin A in generating a response to pneumonia vaccines. The research found that poor regulation of gut microbiota can lead to an inadequate immune response, leaving individuals vulnerable to respiratory infections.
A new type of antibody that stimulates the immune system to target cancer cells has shown promise in reducing tumor growth in treatment-resistant breast and ovarian cancers. The study found that the antibody, IgE, uniquely stimulated otherwise inactive immune cells to directly target HER2-expressing cancer cells.
A study published in Human Gene Therapy found that over half of individuals with Niemann-Pick disease type C1 lacked neutralizing antibodies against AAV2 and AAV9. This absence of antibodies may impact the effectiveness of gene therapy treatments for this rare disorder.
Researchers at Vanderbilt University Medical Center aim to use artificial intelligence technologies to generate antibody therapies against specific antigen targets. The project, funded by $30 million from ARPA-H, will create a massive antibody-antigen atlas and develop AI-based algorithms to engineer antigen-specific antibodies.
Researchers at Stanford University have discovered a method to use two antibodies to effectively combat the constantly evolving virus, which could lead to longer-lasting treatments for COVID-19. The antibodies were shown to be effective against all SARS-CoV-2 variants in laboratory testing.
Researchers have identified powerful antibodies capable of neutralizing a wide range of norovirus strains, paving the way for designing a broadly effective norovirus vaccine. The discovery brings us closer to a vaccine that could provide lasting protection and prevent devastating effects of norovirus outbreaks.
Richard Willson, a University of Houston professor, has been elected Fellow of the Royal Society of Chemistry for his contributions to the chemical sciences. He has developed innovative methods to detect viruses and other biological threats using glow-in-the-dark nanoparticles.
Researchers at La Jolla Institute for Immunology have discovered a human antibody called mAb 3A6 that may prove useful against deadly outbreaks. The antibody was isolated from an Ebola survivor and found to block infection by binding to the viral stalk, offering protection at a very low dose.
The collaboration aims to accelerate antibody discovery and development using Harbour BioMed's technology platform and Insilico's AI expertise. The companies will develop next-generation AI-powered antibodies for immunology, oncology, and neuroscience, aiming to deliver innovative therapies with enhanced specificity, efficacy, and safety.
Scientists at Nagoya University have developed a new mRNA technology that can produce up to 200 times more protein than traditional methods. This breakthrough enables the creation of healthy proteins to treat illnesses or toxic proteins to kill unwanted cells.
A team of researchers has identified a new chronic blood clotting disorder, VITT-like monoclonal gammopathy of thrombotic significance (MGTS), characterized by antibodies similar to those causing vaccine-induced immune thrombocytopenia and thrombosis (VITT). The disorder can lead to severe symptoms despite treatment with full-dose bloo...